Filing identity and reporting period
The supplied filing is Nuvilex, Inc.’s Form 10-K for the fiscal year ended April 30, 2012, filed August 14, 2012. It does not appear to be a Pharmacyte Biotech, Inc. filing, and it is an annual report rather than a 2011 fourth-quarter report.
Nuvilex described itself as an emerging biotechnology and life-technology company, alongside consumer healthcare and environmental products. Its strategy centered on acquiring Austrianova Singapore Private Limited (ASPL) and developing the Cell-in-a-Box live-cell encapsulation technology.
Financial performance and liquidity
| Metric | FY ended April 30, 2012 | FY ended April 30, 2011 |
|---|---|---|
| Revenue | $66,558 | $125,997 |
| Gross profit | $47,175; approximately 70.9% margin | $93,893; approximately 74.5% margin |
| Operating expenses | $1,996,357 | $482,254 |
| Loss from operations | $(1,949,182) | $(388,361) |
| Net loss | $(1,899,312) | $(1,397,716) |
| Operating cash flow | $(259,289) | $(225,232) |
| Cash at year-end | $15,723 | $57,201 |
| Working capital | $(2,728,628) | Not clearly stated as a comparative figure |
At April 30, 2012, total assets were $2,087,508 and total liabilities were $3,787,358. Current assets were $1,058,730 versus current liabilities of $3,787,358. The balance sheet lists $2,092,396 as current debt; the debt note reports total debt, including accrued interest and other obligations, of approximately $2.50 million, all classified as current. No long-term debt was reported.
Investing cash use was $871,730, principally the ASPL acquisition prepayment. Financing provided $1,089,541, including related-party loans and cash advances. Cash decreased by $41,478 during the year.
Changes and unusual items
- Total revenue fell about 47% year over year: product sales declined to $66,558 from $75,997, and the prior-year $50,000 royalty revenue did not recur.
- Operating expenses rose to $1,996,357 from $482,254. Compensation expense was $1,160,878, largely reflecting shares issued for compensation; legal and professional fees were $327,158.
- Other income included a $370,619 gain on forgiveness or settlement of debt, partly offset by a $79,503 fixed-asset disposal loss and $241,246 of interest expense. Without the debt gain, the reported net loss would have been higher.
- The company issued 23.575 million shares for officer compensation and 8.55 million shares for services. It also issued shares in connection with advances and debt settlements. Year-end common shares outstanding were 416.3 million.
Outlook, risks, and contingencies
- Management said the company lacked recurring revenue sufficient to cover operating costs and warned that substantial doubt existed about its ability to continue as a going concern. The independent auditor’s report also highlighted this uncertainty.
- On June 21, 2012, after year-end, Nuvilex acquired all of ASPL for 100 million restricted common shares. The agreement required Nuvilex to fund $2.5 million of future ASPL operations, targeted by December 31, 2012, with $60,000 monthly funding in the interim. The filing does not establish that this funding was completed.
- A Cornerstone Bank settlement addressed an approximately $2.0 million obligation. Terms included transfer of the Cherry Hill property for sale proceeds to reduce the debt and a pledge of 14,605,614 Nuvilex shares as collateral. The settlement provided for a two-year stay of execution subject to repayment terms.
- Management’s plans included raising capital, reducing legacy debt, advancing research, seeking contracts, and marketing products. No quantified revenue, earnings, or development guidance was provided.
- Key risks include inadequate capital, dilution from equity issuance, clinical and regulatory uncertainty, competition, product liability, intellectual-property disputes, and dependence on management and distribution partners.
- Management reported that disclosure controls and internal control over financial reporting were not effective at April 30, 2012, citing underdeveloped accounting policies and procedures and the absence of an audit committee financial expert. The auditor did not attest to internal controls.
Important facts for investors to verify
- Confirm the issuer and period: the provided document is Nuvilex’s FY2012 10-K, not a Pharmacyte Biotech filing or a 2011 Q4 report.
- Review the ASPL acquisition documents and verify the status and source of the required $2.5 million funding and monthly advances.
- Verify the current status, balance, and settlement performance of the Cornerstone debt, property transfer, and pledged shares.
- Reconcile the reported debt amounts and classifications across the balance sheet, debt note, and settlement disclosures.
- Assess cash runway, financing needs, share dilution, and the significant equity-based compensation and service costs.
- Check subsequent share counts: the cover page reports 517,820,851 shares outstanding as of August 9, 2012, including shares associated with the ASPL transaction.